Palomo V, Perez DI, Roca C, et al. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J Med Chem. 2017;60(12):4983-5001. doi:10.1021/acs.jmedchem.7b00395.

Palmer WS, Poncet-Montange G, Liu G, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016;59(4):1440-54. doi:10.1021/acs.jmedchem.5b00405.

Nakasone MA, Lewis TA, Walker O, et al. Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. Structure. 2017;25(12):1839-1855.e11. doi:10.1016/j.str.2017.10.007.

Dolciami D, Gargaro M, Cerra B, et al. Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist. ChemMedChem. 2018;13(3):270-279. doi:10.1002/cmdc.201700669.

Agostini M, Schoenmakers E, Beig J, et al. A Pharmacogenetic Approach to the Treatment of Patients With Mutations. Diabetes. 2018;67(6):1086-1092. doi:10.2337/db17-1236.

Nechama M, Kwon J, Wei S, et al. The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. Nat Commun. 2018;9(1):1603. doi:10.1038/s41467-018-03886-6.

Policarpo RL, Decultot L, May E, et al. High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide -Methyltransferase (NNMT). J Med Chem. 2019;62(21):9837-9873. doi:10.1021/acs.jmedchem.9b01238.

Tu D, Zhu Z, Zhou AY, et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013;3(3):747-58. doi:10.1016/j.celrep.2013.01.033.

Olson DE, Wagner FF, Kaya T, et al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem. 2013;56(11):4816-20. doi:10.1021/jm400390r.

Sadaghiani AM, Lee SM, Odegaard JI, et al. Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays. Chem Biol. 2014;21(10):1278-92. doi:10.1016/j.chembiol.2014.08.016.